The Role of Genetics in Premenstrual Dysphoric Disorder
When it comes to premenstrual dysphoric disorder (PMDD), there appears to be a strong genetic link, similar to that observed in premenstrual syndrome (PMS). While an exact percentage is yet to be determined, studies have shown that a significant number of women with PMDD have mothers who also experienced the condition.
Research has identified a specific gene complex known as ESC/E(Z), which seems to play a crucial role in the development of PMDD. This gene complex is responsible for an over-expression of certain genes, leading to cellular differences in women in relation to their menstrual cycles.
This genetic abnormality makes some women more susceptible to the hormonal changes that occur during their menstrual cycles, ultimately resulting in the development of PMDD.
Treating Premenstrual Dysphoric Disorder (PMDD) with Antidepressants
When it comes to managing Premenstrual Dysphoric Disorder (PMDD), the primary goal is to alleviate symptoms and enhance overall quality of life and functionality, both personally and professionally. Upon receiving a confirmed diagnosis from a healthcare professional, the initial course of action typically involves the use of antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs). The purpose of these medications is to alleviate irritability and depressed mood, thereby complementing the effectiveness of other treatment options.